600129.SH上海证券交易所 · 主板 Main
Taiji Group 太极集团
Traditional Chinese Medicine 中药Ⅱ
¥13.34+¥0.01 · +0.08%
Open 开盘
¥13.36
High 最高
¥13.50
Low 最低
¥13.17
Prev Close 昨收
¥13.33
Volume 成交量
627.6万股
Turnover 成交额
¥8,331.1万
Mkt Cap 总市值
¥74亿
P/E 市盈率
105.6×
Recent Activity 近期动态All Filings 全部公告 →
6 significant filings since 31 May 2026: 1 on bankruptcy or restructuring, 2 on share pledge and 2 on pledge released, and 1 other kind. The latest, on 24 Sep 2026: 太极集团关于全资子公司破产重整的进展公告.
自 31 May 2026 起有 6 份重大公告：bankruptcy or restructuring 1 份、share pledge 2 份、pledge released 2 份，另有 1 类。最新一份（24 Sep 2026）：太极集团关于全资子公司破产重整的进展公告。
Price History 价格走势
250 trading days 个交易日 · High 最高 ¥22.38 · Low 最低 ¥11.8612.0014.0016.0018.0020.0022.00
Volume 成交量
7,408.0万
Sep 25Dec 25Mar 26Jul 26Sep 26
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Traditional Chinese Medicine 中药Ⅱ · 66 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥74亿 | ¥60亿 | 22nd highest of 66 · 66 家中第 22 高 | |
| Trailing P/E 市盈率 | 105.6x | 31.9x | 9th highest of 49 · 49 家中第 9 高 | |
| P/B 市净率 | 2.0x | 2.2x | 29th lowest of 65 · 65 家中第 29 低 | |
| Revenue Growth 营收增速 | -10.1% | -7.4% | 28th lowest of 66 · 66 家中第 28 低 | |
| Profit Growth 净利增速 | -36.7% | -0.2% | 18th lowest of 66 · 66 家中第 18 低 | |
| Gross Margin 毛利率 | 32.0% | 56.9% | 8th lowest of 66 · 66 家中第 8 低 | |
| Net Margin 净利率 | 1.7% | 9.6% | 18th lowest of 66 · 66 家中第 18 低 | |
| Return on Equity 净资产收益率 | 2.5% | 3.0% | 30th lowest of 65 · 65 家中第 30 低 | |
| Debt to Assets 资产负债率 | 74.3% | 28.4% | 4th highest of 66 · 66 家中第 4 高 | |
| Grade Score 评级得分 | 27 | 52 | 11th lowest of 66 · 66 家中第 11 低 |
Statement figures are for the period to 30 Jun 2026, filed by 66 of 66 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，66 家同业中 66 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Yunnan Baiyao Group 云南白药 | ¥898亿 | 17.2x | 2.2x | 2.9% | 16.9% | 9.0% | C |
| Zhangzhou Pientzehuang Pharmaceutical 片仔癀 | ¥704亿 | 38.9x | 4.8x | -15.0% | 23.7% | 7.3% | C |
| China Resources Sanjiu Medical 华润三九 | ¥391亿 | 11.9x | 1.7x | 1.4% | 13.3% | 7.3% | C |
| Beijing Tong Ren Tang 同仁堂 | ¥320亿 | 33.0x | 2.3x | -14.2% | 11.2% | 5.2% | D |
| Guangzhou Baiyunshan Pharmaceutical Holdings 白云山 | ¥316亿 | 12.3x | 0.8x | 0.6% | 5.1% | 5.4% | D |
| Dong-E-E-Jiao 东阿阿胶 | ¥290亿 | 16.2x | 2.9x | 3.4% | 27.3% | 8.1% | C |
| Tianjin Pharmaceutical Da Ren Tang 达仁堂 | ¥271亿 | 31.9x | 4.6x | -7.4% | 26.2% | 9.1% | C |
| Shijiazhuang Yiling Pharmaceutical 以岭药业 | ¥253亿 | 18.4x | 2.3x | 0.9% | 18.6% | 6.7% | B |
| Jumpcan 济川药业 | ¥227亿 | 12.4x | 1.6x | -15.3% | 33.6% | 5.3% | C |
| Tasly 天士力 | ¥206亿 | 16.9x | 1.6x | -2.0% | 21.1% | 7.0% | C |
| Jilin Aodong Pharmaceutical Group 吉林敖东 | ¥206亿 | 6.5x | 0.6x | -8.5% | 198.7% | 6.5% | C |
| Guangdong Zhongsheng Pharmaceutical 众生药业 | ¥196亿 | 98.6x | 4.9x | -23.0% | 10.7% | 2.7% | C |
| Kangmei Pharmaceutical 康美药业 | ¥183亿 | 619.6x | 2.5x | -11.1% | 1.6% | 0.5% | D |
| Buchang Pharma 步长制药 | ¥153亿 | 64.8x | 1.5x | -11.7% | 9.2% | 4.9% | D |
| Taiji Group 太极集团 | ¥74亿 | 105.6x | 2.0x | -10.1% | 1.7% | 2.5% | E |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。